Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells

Combination treatment with tyrosine kinase inhibitors (TKIs) and immunotherapies has shown efficacy in the treatment of multiple cancers, but the immunomodulatory effect of TKIs on the tumor cell phenotype remains unknown in hepatocellular carcinoma (HCC). Given that human lymphocyte antigen class I...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Aya, Umemura, Atsushi, Yano, Kota, Okishio, Shinya, Kataoka, Seita, Okuda, Keiichiro, Seko, Yuya, Yamaguchi, Kanji, Moriguchi, Michihisa, Okanoue, Takeshi, Itoh, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385668/
https://www.ncbi.nlm.nih.gov/pubmed/34458148
http://dx.doi.org/10.3389/fonc.2021.707473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385668/
https://www.ncbi.nlm.nih.gov/pubmed/34458148
http://dx.doi.org/10.3389/fonc.2021.707473

Ejemplares similares